Cargando…

Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study

BACKGROUND/OBJECTIVE: This multicenter study aimed to explore the efficacy and toxicity of radioactive Iodine-125 seed implantation for lymph node recurrence in patients with esophageal cancer after external radiotherapy. METHODS: Clinical data of eligible patients from 5 centers in China were retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lirong, Zhao, Xinxin, Tian, Suqing, Zhang, Kaixian, He, Chuang, Feng, Yong, Zhou, Jiawei, Guo, Wenjie, Ji, Zhe, He, Xia, Chen, Guanglie, Wang, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878769/
https://www.ncbi.nlm.nih.gov/pubmed/36698157
http://dx.doi.org/10.1186/s13014-022-02196-y
_version_ 1784878559951585280
author Wu, Lirong
Zhao, Xinxin
Tian, Suqing
Zhang, Kaixian
He, Chuang
Feng, Yong
Zhou, Jiawei
Guo, Wenjie
Ji, Zhe
He, Xia
Chen, Guanglie
Wang, Junjie
author_facet Wu, Lirong
Zhao, Xinxin
Tian, Suqing
Zhang, Kaixian
He, Chuang
Feng, Yong
Zhou, Jiawei
Guo, Wenjie
Ji, Zhe
He, Xia
Chen, Guanglie
Wang, Junjie
author_sort Wu, Lirong
collection PubMed
description BACKGROUND/OBJECTIVE: This multicenter study aimed to explore the efficacy and toxicity of radioactive Iodine-125 seed implantation for lymph node recurrence in patients with esophageal cancer after external radiotherapy. METHODS: Clinical data of eligible patients from 5 centers in China were retrospectively reviewed. A total of 126 patients between January 2016 and March 2019 were included. The median interval between previous radiotherapy and radioactive Iodine-125 seed implantation was calculated. The target volume was 2.1–128.1 cm(3) (median, 22.2 cm(3)) and the median postoperative D90 is 120.6 Gy (range, 101.7–192). Short-term efficacy of tumor response, the long-term efficacy of local progression-free survival (LRFS) and overall survival (OS), and treatment-related toxicity were reported. RESULTS: For tumor response, 37 (29.4%), 51 (40.5%), 14 (11.1%), and 24 (19.0%) patients achieved complete response, partial response, stable disease and progressive disease, respectively. The 1-, 2- and 3-year LPFS and OS rates were 48.8%, 23.0% and 15.9%, and 80.2%, 38.8%, and 24.5%, respectively. Multivariate analysis identified Karnofsky performance status (P = 0.041) and tumor response (P = 0.049) as independent prognostic factors for LPFS; initial tumor stage (P = 0.034), lesion volume (P = 0.017), and tumor response (P = 0.004) as independent prognostic factors for OS. In total, 77 (61.1%) patients suffered from skin reactions and the incidence of grade 3–5 skin toxicity was 5.6% (7/126). CONCLUSION: Radioactive Iodine-125 seed implantation seems efficient with acceptable toxicity for the treatment of lymph node recurrence secondary to esophageal cancer. A head-to-head study is needed to further evaluate the survival benefit.
format Online
Article
Text
id pubmed-9878769
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98787692023-01-27 Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study Wu, Lirong Zhao, Xinxin Tian, Suqing Zhang, Kaixian He, Chuang Feng, Yong Zhou, Jiawei Guo, Wenjie Ji, Zhe He, Xia Chen, Guanglie Wang, Junjie Radiat Oncol Research BACKGROUND/OBJECTIVE: This multicenter study aimed to explore the efficacy and toxicity of radioactive Iodine-125 seed implantation for lymph node recurrence in patients with esophageal cancer after external radiotherapy. METHODS: Clinical data of eligible patients from 5 centers in China were retrospectively reviewed. A total of 126 patients between January 2016 and March 2019 were included. The median interval between previous radiotherapy and radioactive Iodine-125 seed implantation was calculated. The target volume was 2.1–128.1 cm(3) (median, 22.2 cm(3)) and the median postoperative D90 is 120.6 Gy (range, 101.7–192). Short-term efficacy of tumor response, the long-term efficacy of local progression-free survival (LRFS) and overall survival (OS), and treatment-related toxicity were reported. RESULTS: For tumor response, 37 (29.4%), 51 (40.5%), 14 (11.1%), and 24 (19.0%) patients achieved complete response, partial response, stable disease and progressive disease, respectively. The 1-, 2- and 3-year LPFS and OS rates were 48.8%, 23.0% and 15.9%, and 80.2%, 38.8%, and 24.5%, respectively. Multivariate analysis identified Karnofsky performance status (P = 0.041) and tumor response (P = 0.049) as independent prognostic factors for LPFS; initial tumor stage (P = 0.034), lesion volume (P = 0.017), and tumor response (P = 0.004) as independent prognostic factors for OS. In total, 77 (61.1%) patients suffered from skin reactions and the incidence of grade 3–5 skin toxicity was 5.6% (7/126). CONCLUSION: Radioactive Iodine-125 seed implantation seems efficient with acceptable toxicity for the treatment of lymph node recurrence secondary to esophageal cancer. A head-to-head study is needed to further evaluate the survival benefit. BioMed Central 2023-01-26 /pmc/articles/PMC9878769/ /pubmed/36698157 http://dx.doi.org/10.1186/s13014-022-02196-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, Lirong
Zhao, Xinxin
Tian, Suqing
Zhang, Kaixian
He, Chuang
Feng, Yong
Zhou, Jiawei
Guo, Wenjie
Ji, Zhe
He, Xia
Chen, Guanglie
Wang, Junjie
Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title_full Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title_fullStr Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title_full_unstemmed Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title_short Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
title_sort efficacy and toxicity of iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878769/
https://www.ncbi.nlm.nih.gov/pubmed/36698157
http://dx.doi.org/10.1186/s13014-022-02196-y
work_keys_str_mv AT wulirong efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT zhaoxinxin efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT tiansuqing efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT zhangkaixian efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT hechuang efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT fengyong efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT zhoujiawei efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT guowenjie efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT jizhe efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT hexia efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT chenguanglie efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy
AT wangjunjie efficacyandtoxicityofiodine125seedimplantationforlymphnoderecurrencesecondarytoesophagealcancerafterradiotherapyamulticenterretrospectivestudy